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Summary
Objectives:  Recurrence  is  observed  in  15—20%  of  patients  under  surveillance  following  treat-
ment of  differentiated  thyroid  cancer  (DTC).  However,  due  to  cell  dedifferentiation,  the
recurrence  may  be  iodine-negative,  thereby  compromising  detection.  For  this  reason,  new
methods of  exploration  are  indispensable  to  enable  localization  of  such  recurrences.  The  pur-
pose of  this  work  is  to  review  the  contribution  of  positron  emission  tomography—computed
tomography  (PET-CT)  in  the  exploration  of  iodine-negative  recurrent  DTC.
Method:  A  comprehensive  review  and  discussion  of  the  medical  literature  was  carried  out.
Results: Depending  on  the  report,  the  sensitivity  of  PET-CT  ranged  from  70%  to  85%,  with  up
to 90%  speciﬁcity.  However,  the  large  number  of  false  negatives,  which  can  reach  40%,  is  the
disadvantage  of  this  examination.  PET-CT  results  lead  to  change  in  the  therapeutic  strategy
in approximately  50%  of  patients  with  isolated  raised  serum  thyroglobulin  levels,  and  surgical
exploration  of  a  precise  anatomical  area  in  the  neck.
Conclusion:  As  post-treatment  recurrence  of  a  DTC  can  affect  patient  survival,  a  thorough
diagnostic  work-up  is  required  in  these  cases.  Where  thyroglobulin  levels  are  elevated  with  no
uptake on  131-iodine  scans,  PET-CT  can  be  a  useful  complementary  exploration,  especially  for
localizing the  site  of  recurrence.
r  Ma©  2012  Published  by  Elsevie∗ Corresponding author. Tel.: +33 4 67 33 68 03;
fax: +33 4 67 33 67 28.
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ntroductionhe  prognosis  is  generally  good  for  patients  with  diffe-
entiated  thyroid  cancer  (DTC),  but  long-term  surveillance
s  required  for  several  years  [1,2]. According  to  various
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eports,  recurrence  will  develop  in  15—20%  of  patients  given
he  standard  ﬁrst-line  treatment  by  surgery  and  radioiodine
herapy  [1—4]. The  rate  of  recurrence  depends  on  the  type
f  surgery  performed  initially:  it  is  signiﬁcantly  lower  after
otal  thyroidectomy  (10%)  than  after  lobectomy  (26%)  [4].
ther  factors  of  recurrence  have  also  been  demonstrated,
ncluding  the  presence  of  lymph  node  metastasis  at  initial
urgery,  tumor  size  larger  than  3  cm  and  extrathyroid  exten-
ion  [5].  In  two-thirds  of  patients,  the  recurrence  is  located
n  the  thyroidectomy  bed  or  in  adjacent  lymph  nodes  in  the
eck  and,  thus,  is  accessible  to  surgery  [3,6—8]. Surgery
s  the  preferred  therapeutic  option  when  DTC  persists  or
ecurs  after  ﬁrst-line  treatment,  as  demonstrated  by  ele-
ated  serum  thyroglobulin  (Tg)  levels  in  patients  with  a
egative  radioiodine  scan  [6].
The  pretherapeutic  work-up  should  provide  a  precise
ocalization  of  suspected  areas  of  recurrence.  Positron  emis-
ion  tomography—computed  tomography  (PET-CT)  may  be
seful  in  particular  situations  after  total  thyroidectomy
hen  Tg  levels  rise  without  pathological  131-iodine  uptake
3],  conditions  that  can  compromise  the  diagnosis  of  recur-
ence  [3].  Thus,  the  purpose  of  the  present  review  of  the
iterature  was  to  evaluate  the  usefulness  of  PET-CT  in  these
peciﬁc  situations.
iagnosis of  recurrence
ong-term  follow-up  is  necessary  to  ensure  early  recog-
ition  of  recurrences.  It  is  generally  accepted  that  the
iagnosis  of  recurrence  can  be  established  by  regular  clin-
cal  surveillance  using  ultrasound  (US)  and  Tg  assay  (after
otal  thyroidectomy).  A  detectable  stimulated  or  baseline
erum  Tg  level  more  than  2.0  ng/mL  is  correlated  with
ecurrence  in  98%  of  cases  [1].  Thus,  in  patients  without  thy-
oglobulin  antibodies,  an  elevated  serum  Tg  level  observed
uring  replacement  therapy  or  following  a  stimulation  test
treatment  withdrawal  or  stimulation  with  recombinant
uman  thyroid-stimulating  hormone  [TSH,  thyrotropin  alfa,
hyrogen®,  genzyme])  requires  further  exploration  to  iden-
ify  possible  recurrence  or  metastatic  spread.  It  is  known
hat  an  increased  Tg  level  associated  with  the  presence  or
ecurrence  of  thyroid  tissue  is  correlated  with  reduced  sur-
ival  [9—11]. In  addition,  mortality  due  to  recurrent  DTC
ncreases  with  time,  reaching  15—25%  15  years  after  the  ini-
ial  treatment  [2,11,12],  and  especially  in  cases  of  repeated
ecurrence.  For  this  reason,  detection  is  crucial.  Conven-
ional  imaging  (US,  CT,  magnetic  resonance  imaging  [MRI])
hould  be  performed  and  completed  with  a  131-iodine  scan.
owever,  such  scans  are  positive  for  iodine  uptake  in  only
0—70%  of  cases  of  recurrence  [13]. In  their  study,  Hamy
t  al.  [14]  found  that  recurrence  was  revealed  only  by  an
levated  Tg  level  in  35%  of  patients.
The  131-iodine  whole  body  scan  provides  an  image  of  thy-
oid  tissue  metabolism  and  localization.  If  residual  thyroid
issue  is  functional,  then  iodine  uptake  will  be  visualized;
ne  or  two  sessions  of  radioiodine  therapy  may  be  prescribed
o  lower  serum  Tg  levels  to  below  the  detection  threshold.Nevertheless,  in  certain  patients,  elevated  Tg  levels  per-
ist  despite  a  ‘‘negative’’  scan.  This  can  reﬂect  tumor
ecurrence  with  dedifferentiated,  poorly  differentiated  or
ndifferentiated  cells.  In  this  case,  the  tumor  cells  secrete
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g, but  lose  their  avidity  for  iodine.  Such  iodine-negative
umors  are  more  aggressive  and  associated  with  a  poorer
rognosis  than  iodine-positive  tumors  [11,13]. Furthermore,
ecause  of  differences  in  tumor  size  and  differentiation,  all
ecurrent  localizations  in  a  given  patient  may  not  exhibit
odine  uptake  [14]. This  type  of  recurrence  requires  adapted
iagnostic  and  therapeutic  management.  Surgery  plays  a
redominant  role  in  this  setting,  as  radioactive  iodine,
ven  when  given  at  a  high  dose,  fails  to  lower  Tg  levels
to  <  5  ng/mL)  in  more  than  50%  of  patients  [12,14,15]. In
0%  of  cases,  these  recurrences  involve  lymph  nodes,  gene-
ally  in  the  central  or  lateral  regions  of  the  neck,  that  are
ccessible  to  surgery.  A  precise  map  of  the  tissue  involved
n  recurrence  is  thus  needed.
Conventional  imaging  methods,  especially  US,  enable
on-invasive  exploration  of  the  cervical  region.  US  can
emonstrate  the  presence  of  65%  of  non-palpable  neck
etastases  with  a  94%  positive  predictive  value  [16]. Cha-
acteristic  US  features  correlated  with  malignancy  include
umor  size  larger  than  6  mm  (smallest  dimension),  spherical
ymph  nodes,  presence  of  microcalciﬁcations,  absence  of  an
chogenic  hilus,  cyst  formation  and  central  vascularization
1,13,17].  In  one  US  study  devoted  speciﬁcally  to  recurrence
n  the  thyroidectomy  bed,  central  vascularization  and  tumor
ize  less  than  6  mm  were  found  to  be  highly  sensitive  fac-
ors  of  recurrence  [17]. US  can  be  coupled  with  ﬁne-needle
spiration  cytology  and  assay  of  intranodular  Tg  to  improve
he  diagnostic  power  [1,18]. The  ﬁeld  of  US  exploration  is,
owever,  limited  to  the  neck,  which  contains  certain  areas
retrotracheal  area,  cervicothoracic  junction)  where  inter-
retation  is  difﬁcult  [7].  Postoperative  remodeling  of  the
hyroidectomy  bed  and  lymph  node  level  VI  also  affects  US
erformance  [1,18]. Nevertheless,  in  the  context  of  recur-
ence  in  the  thyroidectomy  bed,  US  demonstrates  consistent
fﬁcacy  in  detecting  very  small  structures  [17].
Tomography  methods  including  injection  of  contrast
gents  and  MRI  with  gadolinium  can  be  helpful  in  patients
ith  negative  radioiodine  scans.  However,  because  of  post-
perative  remodeling,  these  explorations  exhibit  limited
ensitivity  and  speciﬁcity  at  surgical  sites  [18]. Neverthe-
ess,  ﬁnding  spherical  nodes  with  more  or  less  pronounced
on-homogeneous  enhancement  is  highly  suggestive  and
ay  help  to  guide  surgery  [18]. Still,  the  surgeon  must
eigh  the  risks  against  the  beneﬁts  of  a second  proce-
ure  performed  on  remodeled  tissue  and  undertaken  for
oth  diagnostic  and  therapeutic  purposes,  while  keeping  in
ind  the  possible  non-pathological  nature  of  certain  nodal
mages.
PET-CT  with  18-ﬂuoro-2-deoxyglucose  (18FDG)  is  an
maging  method  that  enables  detection  of  cell  hyperme-
abolism  in  tissues  with  suspected  malignancy.  Diagnostic
apping  has  been  improved  by  the  development  of  tech-
ology  that  makes  it  possible  to  fuse  PET  and  CT  images
19]. Studies  have  focused  on  correlating  PET-CT  data  with
istological  ﬁndings  after  revision  surgery.  For  recurrent
odine-negative  thyroid  cancer,  reports  of  PET-CT  sensitivity
ave  ranged  from  70—85%  with  90%  speciﬁcity  [19]  (Table  1).
ccording  to  the  meta-analysis  presented  by  Miller  et  al.  in
011  [20], model  sensitivity  was  77%  with  85%  speciﬁcity.
he  number  of  false  negatives  is,  however,  a  limitation  of
ET-CT  explorations,  and  a  few  cases  of  false  positives  may
ead  to  unnecessary  second  operations  [21—26]  (Fig.  1).
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Table  1  Positron  emission  tomography—computed  tomography  in  radioiodine-negative  recurrent  differentiated  thyroid  cancer
according to  sensitivity,  speciﬁcity,  positive  predictive  value  (PPV)  and  negative  predictive  value  (NPV).
Reference Number  of  cases Sensitivity  Speciﬁcity  PPV  NPV
Mirallié  et  al.  [13] 45  63  —  77  —
Freudenberg  et  al.  [32] 36 96 100 100 93
Nahas  et  al.  [22] 33 66 100 100 27
Palmedo  et  al.  [19]  40  95  91  86  95
Shammas et  al.  [16]  59  68  82  73  —
Zoller et  al.  [9]  33  74  —  —  —
80.
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Helal  et  al.  [27]  reported  false  positives  in  13%  of  patients
with  elevated  Tg  and  negative  131-iodine  scans;  at  surgery,
all  of  the  nodes  in  these  patients  were  inﬂamed.  In  2010,
Razfar  et  al.  [10]  presented  the  results  of  a  large  series  of
124  patients  whose  Tg  levels  rose  after  ﬁrst-line  treatment;
80%  of  these  patients  had  negative  131-iodine  scans.  Tumor
recurrence  was  eventually  identiﬁed  in  71  of  75  patients
with  a  positive  PET-CT  scan.  Among  the  49  patients  who  had
no  PET-CT  examination,  32  were  considered  true  negatives
(Tg  remained  stable  at  2.0—8.0  ng/mL  with  no  observed
recurrence).  In  the  other  17  patients  with  negative  PET-CT
scans,  recurrence  was  ﬁnally  identiﬁed  in  nine  patients  by  US
and  CT.  Only  one  recurrence  was  observed  among  the  other
eight  patients.  In  this  large  cohort,  the  positive  predictive
value  of  PET-CT  was  94.7%,  while  the  negative  predictive
value  was  65.3%  [10]. To  increase  sensitivity  and  speciﬁcity,
the  authors  recommended  PET-CT  for  patients  with  serum
s
t
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Figure  1  Positron  emission  tomography—computed  tomography  sca
thyroglobulin;  the  131-iodine  scan  was  negative.7  88.9  94.7  65.3
g more  than  10  ng/mL  or  rising  on  repeated  controls.  In  a
tudy  by  Zoller  et  al.  [9]  of  47  patients,  they  found  that  PET-
T  sensitivity  was  22%  for  Tg  less  than  20  ng/mL  and  88%  for
g  more  than  20  ng/mL.
18FDG  sensitivity  was  higher  in  patients  with  dediffe-
entiated  metastases  and  negative  iodine  scans  [28]. Cell
edifferentiation  may  be  expressed  by  increased  metabolic
ctivity  (with  increased  avidity  for  18FDG)  and  a  loss  of  avid-
ty  for  iodine  uptake,  a  phenomenon  known  as  ‘‘ﬂip-ﬂop
etastasis’’  [22,23]  (Figs.  2  and  3).  Detection  of  iodine-
egative  metastases  can  be  further  improved  with  the
se  of  recombinant  TSH  (Thyrogen®,  genzyme).  Survival
s  decreased  in  patients  with  recurrence  exhibiting  18FDG
ptake  on  PET-CT  scans  because  of  the  inverse  relation-
hip  between  survival  and  lesion  avidity  (as  measured  by
he  standard  uptake  value  (SUV])  and  the  number  of  high-
ptake  lesions  [26,29].  A  multiparameter  study  of  400  cases
ns  showing  left  paratracheal  uptake  in  a  patient  with  elevated
254  
Figure  2  Negative  131-iodine  scan  with  elevated  thyroglobu-
lin.
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tion,  PET-CT  can  provide  supplementary  information  usefuligure  3  Positron  emission  tomography—computed  tomogra-
hy of  the  same  patient  as  in  Fig.  2  showing  an  8-mm  lesion  and
8-FDG  uptake  in  the  left  thyroidectomy  bed.
f  DTC  demonstrated  that  factors  predictive  of  survival  were
ge,  18FDG  avidity1,  number  of  18FDG-avid  lesions  and  the
UVmax [26]. Median  survival  among  cases  of  18FDG-positive
esions  was  53  months  after  the  PET-CT  scan  in  contrast  to
wo  deaths  out  of  180  cases  of  18FDG-negative  lesions  [26].Where  the  only  anomaly  is  a  rise  in  serum  Tg  levels,
ET-CT  results  can  lead  to  a  change  in  therapeutic  mana-
ement  [16]. This  may  involve  a  decision  for  surgery,
1 L’auteur cité (Robbins [26]) a utilisé le terme « positivity » et
on « avidity ».
f
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xternal  radiation  therapy  or  targeted  therapy,  depend-
ng  on  the  18FDG-PET  ﬁndings  after  a  negative  work-up
radioiodine  scan,  US)  [16,20]. PET-CT  is  particularly  useful
hen  exploring  remodeled  tissue  such  as  the  thyroidectomy
ed  [11,13,20]. However,  recurrences  of  initially  strongly
8FDG-positive  differentiated  cancers  are  not  especially2
ensitive  to  administration  of  high-dose  radioactive  iodine.
ased  on  this  observation,  it  seems  logical  to  propose
otentially  curative  surgery  for  18FDG-positive  recurrences
10].  Studies  reporting  such  appropriately  adapted  thera-
eutic  strategies  have  found  rates  ranging  from  20%  to  55%
16,19,22,26,27,29—31].  In  2005,  Nahas  et  al.  [22]  found
hat  the  treatment  plan  was  changed  in  40%  of  patients
ith  suspected  recurrence  based  on  an  isolated  increase
n  TSH  level.  In  2007,  Mirallie  et  al.  [13]  reported  that
ET-CT  enabled  a  decision  for  surgery  in  45%  of  patients
ith  elevated  serum  Tg  and  negative  radioiodine  scans.
n  2004,  Hamy  et  al.  [14]  recommended  that  the  neck
egions  should  be  re-explored  in  this  type  of  situation,
lbeit  while  recognizing  that  this  would  increase  the  risks  of
ypoparathyroidism,  recurrent  injury  and  either  not  ﬁnding
r  incompletely  treating  recurrences.  Nevertheless,  PET-CT
nabled  the  detection  of  unique  or  multiple  recurrences
ot  seen  on  US  or  radioiodine  scans  [13]. The  observed  dif-
erences  in  sensitivity,  speciﬁcity  and  rates  of  change  in
reatment  plans  were  interpreted  as  being  linked  to  diffe-
ences  in  Tg  levels  at  the  time  of  the  PET-CT  scan  and  to  the
act  that,  in  most  studies,  the  data  were  retrospective  with
o  distinctions  made  between  different  histological  forms
20]. The  10  ng/mL  cut-off  for  Tg  would  be  the  minimum
elow  which  PET-CT  should  become  a  systematic  exploration
28].
Another  contribution  of  PET-CT  is  the  detection  of  distant
odine-negative  metastases.  In  these  cases,  18FDG  avidity
s  strongly  correlated  with  survival  [10,26]. Nevertheless,
he  relationship  between  PET-CT  and  the  detection  of  small
esions  measuring  less  than  5  mm  and  the  demonstration  of
iliary  lung  metastases  has  proved  to  be  limited  [9,19].
elical  CT  exhibits  better  performance  in  these  situations
32].
ractical changes
efore  the  advent  of  PET-CT,  surgery  was  generally  pro-
osed  after  US  and  perhaps  ﬁne-needle  biopsy  for  patients
ith  elevated  serum  Tg  and  negative  131-iodine  scans.  The
bjective  was  to  re-explore  the  neck  or  anatomical  areas  not
xplored  during  the  ﬁrst  procedure,  as  recurrences  are  often
ound  in  the  neck  [9,14]. Yet,  despite  multiple  explorations
US,  131-iodine  whole  body  scans,  CT),  a  large  percentage
f  lymph-node  metastases  go  undetected:  28.8%  according
o  Hamy  et  al.  [14]  and  26%  according  to  Baudin  et  al.
33].  Currently,  after  US  exploration  with  ﬁne-needle  aspira-or  precise  surgical  guidance  to  explore  18FDG-avid  areas
14].  As  reported  by  Zoller  et  al.  [9],  if  PET-CT  fails  to
2 Cela est la traduction correcte du franc¸ais. Quelle est la question
osée ?
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[PET-CT  evaluation  for  recurrent  differentiated  thyroid  carci
visualize  any  signiﬁcant  uptake,  then  surgery  is  not  neces-
sary  to  re-explore  the  neck.
When  an  elevated  Tg  level  is  associated  with  an  image
suggestive  of  malignancy,  the  surgeon  needs  to  distinguish
between  two  situations,  as  the  risk  of  complications  depends
on  whether  or  not  the  area  to  be  re-explored  was  involved
in  the  ﬁrst  operation.  Two  areas  of  recurrence  may  be
noted:  the  jugulocarotid  nodes  (involved  or  not  in  the
ﬁrst  dissection);  and  the  previously  dissected  thyroidec-
tomy  bed.  If  the  uptake  on  the  PET-CT  scan  corresponds
to  a  surgery-naive  anatomical  area,  then  regional  surgery
and/or  complete  node  dissection  should  be  proposed,  tak-
ing  into  consideration  the  surgical  risks  directly  related  to
the  anatomical  area  involved.  In  most  cases,  this  occurs
when  recurrence  involves  either  the  lateral  jugulocarotid
nodes  on  the  side  opposite  the  initial  lesion  or  a  jugulo-
carotid  area  unaffected  by  the  ﬁrst  operation  (levels  I,  IIb,
Va  and  Vb  are  currently  not  dissected  during  ﬁrst-intention
surgery).  Dissection—cavitation  of  an  anatomical  area  bear-
ing  a  focus  of  18FDG  uptake  is  considered  preferable  to
simple  node  resection,  as  all  recurrences  are  not  necessarily
visualized  by  the  imaging  procedure  [14,34].  In  a  surgery-
naive  anatomical  area,  surgery  can  be  performed  under  the
usual  conditions  with  no  supplementary  postoperative  risk.
Where  a  recurrence  is  detected  in  a  previously  operated
area,  the  operation  will  be  more  difﬁcult,  with  an  increased
risk  of  postoperative  complications.  In  general,  this  situation
is  encountered  when  recurrence  involves  the  thyroidectomy
bed  or  a  paratracheal  site  [35,36].  The  difﬁculty  of  a  sec-
ond  operation  may  be  considerable  because  of  postope-
rative  ﬁbrosis,  and  the  proximity  of  the  recurrent  nerves  and
parathyroid  glands.  Dissection  of  scar  tissue,  identiﬁcation
of  the  recurrent  nerves  and  the  parathyroids,  and  identiﬁca-
tion  of  recurrent  injury  may  all  become  more  problematical.
In  most  cases,  recurrence  involves  a  lymph  node  in  the
anatomical  area,  especially  in  the  inferior  region  where
the  proximity  of  the  cervicothoracic  vessels  can  complicate
the  exposure  [6,36,37].  Carcinological  dissection  is  the  rule
while  also  attempting  to  limit  postoperative  complications
[36]. In  these  situations,  surgical  experience  and  moni-
toring  of  the  inferior  laryngeal  nerve  are  important  for
reducing  postoperative  complications  [37]. Compared  with
the  primary  operation,  reopening  the  thyroidectomy  bed
increases  the  risk  of  permanent  injury  to  the  inferior  laryn-
geal  nerve  and  parathyroid  glands,  such  as  recurrent  palsy
in  10%  of  cases  and  hypoparathyroidism  in  12%  [29,31,37].
To  reduce  such  risks,  it  is  advisable  to  perform  a  procedure
strictly  limited  to  the  structures  exhibiting  tracer  uptake.
The  contribution  of  PET-CT  imaging  in  these  cases  towards
identifying  suspect  sites  [10]  after  US  is  undeniable  and  is,
in  the  case  of  recurrence  in  the  thyroidectomy  bed,  always
effective  in  detected  small-sized  structures  [17].
After  surgery,  the  stimulated  Tg  level  is  an  effective
marker  of  surgical  efﬁcacy  and  also  a  predictive  factor  of
another  recurrence  of  recurrent  DTC  [6].
ConclusionThe  recurrence  of  DTC  during  post-treatment  follow-up
requires  a  speciﬁc  diagnostic  approach.  PET-CT  is  an
important  exploratory  method  that  is  complementary  to
[a  255
adioiodine  whole  body  scans  and  standard  US.  Its  contri-
ution  is  particularly  useful  for  the  diagnosis  of  radioiodine-
egative  metastases.  A  combination  of  metabolic  and  CT
mages  further  improves  identiﬁcation  of  recurrent  or
etastatic  tissue,  thus  providing  a  precise  map  for  guiding
urgical  procedures.
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